In this video, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, describes an ongoing Phase I dose escalation study which is investigating the safety profile of enitociclib, a selective CDK9 inhibitor, in patients with high-risk chronic lymphocytic leukemia (CLL) and Richter’s syndrome (NCT04978779). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.